Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?

被引：17

作者：

Punt, CJA ^{[1
]}

机构：

[1] Univ Nijmegen, Radboud Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷 / 06期

关键词：

D O I：

10.1093/annonc/mdi196

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：845 / 846

页数：2

共 12 条

[1] PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS [J].

ABIGERGES, D ;

CHABOT, GG ;

ARMAND, JP ;

HERAIT, P ;

GOUYETTE, A ;

GANDIA, D .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :210-221

[2] A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity [J].

Borner, MM ;

Bernhard, J ;

Dietrich, D ;

Popescu, R ;

Wernli, M ;

Saletti, P ;

Rauch, D ;

Herrmann, R ;

Koeberle, D ;

Honegger, H ;

Brauchli, P ;

Lanz, D ;

Roth, AD .

ANNALS OF ONCOLOGY, 2005, 16 (02) :282-288

[3]

CORNELLA P, 2005, ANN ONCOL, V16, P878

[4] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer [J].

Fuchs, CS ;

Moore, MR ;

Harker, G ;

Villa, L ;

Rinaldi, D ;

Hecht, JR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :807-814

[5] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[6]

Grothey A., 2003, EJC Supplements, V1, pS90, DOI 10.1016/S1359-6349(03)90328-4

[7] Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study [J].

Kalofonos, HP ;

Aravantinos, G ;

Kosmidis, P ;

Papakostas, P ;

Economopoulos, T ;

Dimopoulos, M ;

Skarlos, D ;

Bamias, A ;

Pectasides, D ;

Chalkidou, S ;

Karina, M ;

Koutras, A ;

Samantas, E ;

Bacoyiannis, C ;

Samelis, GF ;

Basdanis, G ;

Kalfarentzos, F ;

Fountzilas, G .

ANNALS OF ONCOLOGY, 2005, 16 (06) :869-877

[8] High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study [J].

Merrouche, Y ;

Extra, JM ;

Abigerges, D ;

Bugat, R ;

Catimel, G ;

Suc, E ;

Marty, M ;

Herait, P ;

Mahjoubi, M ;

Armand, JP .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1080-1086

[9] New options and old dilemmas in the treatment of patients with advanced colorectal cancer [J].

Punt, CJA .

ANNALS OF ONCOLOGY, 2004, 15 (10) :1453-1459

[10]

REA DW, 2005, IN PRESS ANN ONCOL, P16

← 1 2 →